3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
20
Rectal Neoplasms
11
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Stomach Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Liver Neoplasms
2
Recurrence
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Neoplasm Recurrence, Local
1
Margins of Excision
1
Locally Advanced Rectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Cyclophosphamide
3
Epirubicin
2
Docetaxel
2
Carboplatin
2
Capecitabine
2
Azacitidine
2
venetoclax
1
tegafur-gimeracil-oteracil
1
taxane
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pirarubicin
1
pertuzumab
1
pembrolizumab
1
olaparib
1
cc-486
1
Trastuzumab
1
Thalidomide
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Methotrexate
1
Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Complete Response
×
Folfox protocol
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled